arrow
A

Arnaud Scherpereel

oncothai inserm
H指数:66
被引数:1.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Club cell secretory protein (CCSP) serum concentration is a prognostic factor after surgical resection of localized non-small cell lung cancer in patients in the IFCT-0302 trial

Club cell secretory protein (CCSP)血清浓度是IFCT-0302试验中局部非小细胞肺癌患者术后切除后的预后因素。

2026-02-240
PRE
Pembrolizumab versus pembrolizumab plus chemotherapy in patients with PDL1 ⩾50% advanced non-small-cell lung cancer, depending on tumor aggressiveness and clinical impact

帕博利珠单抗与帕博利珠单抗联合化疗在PDL1 ⩾50%的晚期非小细胞肺癌患者中的比较,根据肿瘤侵袭性和临床影响

2025-11-300
OA
Life-threatening immune-related adverse events in the intensive care unit: a narrative review

重症监护病房中危及生命的免疫相关不良事件:一项叙述性综述

2025-10-220
PRE
MiR-193b-3p and miR-132-3p as prognostic biomarkers of survival in pleural mesothelioma patients treated with first-line bevacizumab plus pemetrexed-platinum chemotherapy in the IFCT-0701 MAPS phase 3 trial

MiR-193b-3p和miR-132-3p作为IFCT-0701 MAPS III期试验中接受一线贝伐珠单抗联合培美曲塞-铂类化疗的恶性胸膜间皮瘤患者的生存预后生物标志物

2025-09-050
PREAI
Surrogate markers of intestinal dysfunction associated with survival in advanced cancers

与晚期癌症生存相关的肠道功能障碍的替代标志物

2025-04-060
OAAI
Survival and Prognostic Factors After Adrenalectomy for Secondary Malignancy

肾上腺继发性恶性肿瘤切除术后的生存和预后因素

2024-08-070
PRE
Daily Caffeine Consumption May Increase the Risk of Acute Kidney Injury Related to Platinum-Salt Chemotherapy in Thoracic Cancer Patients: A Translational Study

每日摄入咖啡因可能会增加胸部癌症患者与铂盐化疗相关的急性肾损伤的风险: 一项转化研究

2024-03-190
OAAI
Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial
LANCET
IF88.5
2023-12-0113
PRE
Multiomic analysis of malignant pleural mesothelioma identifies molecular axes and specialized tumor profiles driving intertumor heterogeneity
2023-03-1627
OAAI
First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743

一线nivolumab联合ipilimumab与化疗在不可切除的恶性胸膜间皮瘤患者中的比较: CheckMate 743的3年结果

2022-05-01135
OA
A defect of amphiregulin release predicted longer survival independently of YAP expression in patients with pleural mesothelioma in the IFCT-0701 MAPS phase 3 trial
2022-03-161
OA
Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer

肠道Akkermansia muciniphila预测晚期非小细胞肺癌患者对PD-1阻滞的临床反应

2022-02-03298
OA
First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update (vol 6, 100273, 2021)
2021-12-013
OAAI
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update

一线nivolumab联合ipilimumab两周期化疗与单纯化疗 (四个周期) 治疗晚期非小细胞肺癌: CheckMate 9LA 2年更新

2021-10-01145
OAAI